Samsung BiologicsConsolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, Samsung Biologics aims to strengthen its position in the fast-growing market for complex biopharmaceuticals.
Tag Archive for: CDMO
ArdenaAriane de Ganck, PhD, took over the position as new Chief Scientific Officer (CSO) at Ardena. She started in 2019 at the Ghent-based CDMO/CRO.
Rezon BioDr Ralf Otto, a former manager at Boehringer Ingelheim and Rentschler, has been appointed as the new Chief Operating Officer of the Polish company Rezon Bio.
3PBIOVIANEurope continues to play a pivotal role in the global biologics landscape, combining scientific excellence, regulatory maturity and a strong industrial foundation.
Evonik Industries AGEvonik is investing €80 million in its fermentation plant in Slovakia, pushing the Group’s structural transformation forward with a major investment in biotechnology. Alongside spider‑silk proteins from Amsilk, the site is set to offer a broader CDMO portfolio for the pharmaceutical industry.
3PBIOVIAN consolidates its position as a trusted partner for the development and manufacturing of complex biological products, combining scientific excellence, regulatory expertise, and strong social commitment.
Lonza GroupCDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined commitment to its core business. But the stronger investment strategy internationally frightens Switzerland – at least some analysts.
Vetter PharmaWith an initial investment of around €480 million, Ravensburg-based Vetter Pharma has now fleshed out its plans to expand operations in Saarlouis, Saarland. The former automotive site is to be redeveloped by 2031 and is expected to employ up to 2,000 people in contract development and manufacturing.
Rentschler Biopharma SEUnexpected changes at the top of Rentschler Biopharma: CEO Benedikt von Braunmühl and the Supervisory Board agreed on a swift separation in January, and COO Christiane Bardroff is also set to leave the biopharma manufacturer based in Laupheim, Baden-Württemberg, in the near future. The message from within the company: stay calm, it won´t knock us off course.
stock.adobe.photo.com/Popelniushka According to a new deal, AGC Biologics wil manufacture AAVantgarde’s dual AAV gene therapies for inherited retinal diseases using the high-yield BravoAAV™ suspension platform.